Clinical trials: Movement Abnormalities
Parkinson's Disease
Automated Parkinson's Disease (PD) Motor Symptom Assessment for Deep Brain Stimulation (DBS) Programming
The purpose of this study is to evaluate the utility of a portable motion sensor-based system designed to assist with deep brain stimulation (DBS) programming sessions for Parkinson's disease patients.
- Trial name
- NCT01429220
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment.
- Trial name
- CYPRESS (NCT05696717)
- Testing
- Ampreloxetine
- Where
- 79 sites in United States, Argentina and 18 more
- Volunteers
- 102 people
- Sponsor
- Theravance Biopharma
Parkinson Disease
Phase II Clinical Study of TR-012001 in Japanese Patients With Parkinson's Disease
The purpose of this study to evaluate the safety and pharmacokinetics of TR-012001 in patients with Parkinson's disease when TR-012001 or placebo is administered.
- Trial name
- NCT06212089
- Testing
- TR-012001
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- SNLD, Ltd.
Parkinson Disease
A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease
This study is to evaluate the safety and tolerability and to characterize the pharmacokinetics of multiple ascending dose (MAD) of LY03003 following intramuscular injections.
- Trial name
- NCT04045678
- Testing
- LY03003 ( Rotigotine, extended-release microspheres)
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson Disease
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15 milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.
- Trial name
- NCT05610189
- Testing
- Tavapadon
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cerevel Therapeutics, LLC
Huntington Disease
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their…
- Trial name
- NCT06667414
- Where
- 45 sites in United States, Argentina and 10 more
- Volunteers
- 574 people
- Sponsor
- Hoffmann-La Roche
Wilson Disease
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
- Trial name
- NCT04573309
- Testing
- ALXN1840
- Where
- 3 sites in United States, New Zealand and 1 more
- Volunteers
- 9 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Parkinson Disease
A Study of LY03003 in Patients With Early-stage Parkinson's Disease
This study is to characterize the pharmacokinetics and to evaluate the safety as well as tolerability of LY03003 following multiple escalating intramuscular injections
- Trial name
- NCT04044547
- Testing
- Rotigotine, extended-release microspheres
- Volunteers
- 60 people
- Sponsor
- Luye Pharma Group Ltd.
Heart Failure, Myocardial Infarction
A Multinational Trial To Evaluate The Parachute Implant System
The primary objective is to assess the safety of the CardioKinetix Parachute Implant and Delivery System in the partitioning of the left ventricle in patients with heart failure due to ischemic heart disease.
- Trial name
- PARACHUTE (NCT01286116)
- Testing
- Parachute Implant
- Where
- 13 sites in France, Germany and 6 more
- Volunteers
- 59 people
- Sponsor
- CardioKinetix, Inc
Essential Tremor, Movement Disorders
A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
The purpose of this study is to evaluate the effectiveness, safety and tolerability of carisbamate treatment for the signs, symptoms, and impairment associated with Essential Tremor (ET) compared to placebo treatment.
- Trial name
- NCT00524056
- Testing
- Carisbamate
- Volunteers
- 62 people
- Sponsor
- SK Life Science, Inc.
Parkinson Disease
Special Survey on PD Patients With Renal Dysfunction
The survey is conducted to collect safety and effectiveness information targeting patients who have both Parkinson's disease and renal dysfunction treated with Pramipexole in the daily clinical settings in Japan.
- Trial name
- NCT00613756
- Where
- 98 sites in Japan
- Volunteers
- 107 people
- Sponsor
- Boehringer Ingelheim
Parkinson´s Disease
Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
Evaluate the benefits of Kinesia-360™ wearable technology in addition to standard clinical practice on improving Parkinson´s disease motor symptoms, Neupro dosing regimen and adherence to Neupro compared with only standard…
- Trial name
- NCT03103919
- Testing
- Kinesia-ONE™, Kinesia-360™, Rotigotine
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- UCB Biopharma S.P.R.L.
Huntington Disease
A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.
This is a dose escalation and expansion clinical study to evaluate the safety, tolerability, PK profile and preliminary efficacy of ER2001 Injection vs. placebo in subjects with definitive diagnosis of early manifest HD.
- Trial name
- NCT07339514
- Testing
- ER2001 intravenous injection
- Where
- 3 sites in China
- Volunteers
- 27 people
- Sponsor
- ExoRNA Bioscience
Pantothenate Kinase-Associated Neurodegeneration
Compassionate Use of Deferiprone in Patients With PKAN
Patients with pantothenate kinase-associated neurodegeneration (PKAN) who have completed the ApoPharma-sponsored study TIRCON2012V1-EXT and who wish to continue to take deferiprone will be offered the opportunity to receive it on…
- Trial name
- NCT02635841
- Testing
- Deferiprone
- Sponsor
- Chiesi Canada Corp
Parkinson's Disease
A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease
This is a single-center, open label study evaluating the acute effect of caloric vestibular stimulation on UPDRS motor scores in Parkinson's Disease patients.
- Trial name
- NCT02134795
- Testing
- TNM Device
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Scion NeuroStim
Parkinson's Disease
Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
The primary objective of the study is to assess the efficacy, carbidopa dose response and safety of ODM-101, a new combination of levodopa, carbidopa and entacapone in the treatment of Parkinson's disease (PD) patients with…
- Trial name
- PARPOC (NCT01766258)
- Testing
- ODM-101 65mg Carbidopa, ODM-101 105mg Carbidopa, Stalevo
- Volunteers
- 117 people
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson Disease
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.
- Trial name
- NOSE-PD (NCT05266417)
- Testing
- INS-GSH
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Gateway Institute for Brain Research
Metastatic Brain Tumor, Primary Brain Tumor
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical.
- Conditions
- Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
- Trial name
- LAANTERN (NCT02392078)
- Testing
- NeuroBlate System
- Where
- 26 sites in United States
- Volunteers
- 1,153 people
- Sponsor
- Monteris Medical
Huntington's Disease
Efficacy and Safety of Tetrabenazine in Chorea
The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo
- Trial name
- NCT00219804
- Sponsor
- Prestwick Pharmaceuticals
Parkinson's Disease
Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients
The purpose of this study is to evaluate whether the DopaFuse System can reduce the fluctuation of plasma levodopa levels compared to participants' standard intermittent doses of oral LD/CD tablets (background treatment).
- Trial name
- SCOL (NCT04778176)
- Testing
- continuous oral delivery of levodopa/carbidopa
- Where
- 5 sites in Italy, Luxembourg and 1 more
- Volunteers
- 17 people
- Sponsor
- SynAgile Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.